Autonomix Medical, Inc. · NASDAQ:AMIX
Autonomix Medical — Investor Presentation (January 2025)
18 slides from Autonomix Medical's investor presentation, Jan 22, 2025
Slide 1: Sense, Treat and Verify: Investor Presentation January 2025
Nasdaq: AMIX ‘autonomix.com AUTONOMIX Sense, Treat and Verify. Illuminating the Nervous System with Transvascular Precision-Guided Technology Investor Presentation January 2025
Slide 2: Disclaimer
Disclaimer {Al statements contained herein other than statements of historical fact, including statements rogarding our future results of operations and oe “open ‘and trends that we “may? “will” “estimate” “continue,” “anticipa We have ‘nd financial needs. These statements are only predictions and i
Slide 3: Unleashing the Power of Autonomix Treatments
Unleashing the Power of AUTONOMIX Treatments ly technology to treat neurological diseases 120+ Patents Extensive IP Portfolio with 120+ Patents Issued and Pending 00x Nase Sena Anat arid Veifcaon Sytem 3.000 Ties More = Sensitive than Current Technol 2026 FDA SRR Targeting FDA De Novo Submission in
Slide 4: Current Technologies Cannot Precisely Target and Treat Overactive Nerves
Current Technologies Cannot Precisely Target and Treat Overactive Nerves Current cardiac sensing technologies cannot detect low amplitude neuronal signals Neuronal RF ablation procedures, while effective, are currently performed blind Clearer visibility anda better understanding of the /stem can ope
Slide 5: Autonomix Nervous System Technology
AUTONOMIX \tuminating the Ni Technology > Grvronomix
Slide 6: Sense, Treat and Verify
elas Sense, — and Verify 1p) atient Through Precision-Guided Treatment 1 Sense (Identify) 2 Treat (Ablate) 3 Verify (Confirm) Overactive Nerves Target Nerves Treatment Precision Mapping of Neural Activity to Identify Target Delivers Thermal Energy to Kill Fe Treatment “Targst Nerves Effectiveness. ‘
Slide 7: Unleashing the Power of Precision-Guided Nerve-Targeted Treatments
Unleashing the Power of Precision-Guided Nerve-Targeted Treatments Catheter-Based Technology to Detect Relevant Neuronal Signals and Ablate Nerves in One Simple Procedure 1-2uV 3,000x' f Platform Ability to Detect and 3,000 Times Greater Unlimited Application Differentiate Neural Sensitivity Than Cu
Slide 8: Processing Power Brought Directly to the Nerves
Processing Power Brought Directly to the Nerves ifaw gee Signal travels 6 feet tobe processed 7 Stronger cardiac electrical activity is capable §—§ >——-—-— Of traveling distance without loss of signal and resolution. CURRENT | dex Signal travels Millimeters to be processed neuronal el iL he sensor r
Slide 9: Initially Targeting Treatment of Pancreatic Cancer Pain
Initially Targeting Treatment of Associated With Demonstrated Significant Pain Reduction in Initial Patients Topline Results Expected in 1H 2025 Number of Subjects: 25) Clinical Sites: 1 Objective: Ablate relevant nerves and mitigate intractable pain {elas 2: Pancrase cance stsbtcs, WOE nteratna B4,
Slide 10: Groundbreaking Positive Results Highlight Significant Impact on Pancreatic Cancer Pain
Groundbreaking Positive Results Highlight Significant impact on Treatment of Pancreatic Cancer Pain Positive 7-Day Follow-Up From First 15 Patients in Clinical Evaluation Group 79% responded 100% of the with a mean 4.96, subjects or 63%, reduction responded in VAS pain score with femoral access 73%
Slide 11: Significant Reduction in Pain With Improvement in Quality of Life
in Pain With Improvement in Quality of Life Ongoing Proof-of-Concept Clinical Trial in Pain Associated with Pancreatic Cancer 7-Day Data 4-6 Week Data tudyGroup VAS Pain Score First 5 ¥ Positive Reduction 86% ¥ Positive Reduction Lead-In 60% vZero sabes 6.33 or 79% Improvement | 6:67 0F 83% Y Positi
Slide 12: Demonstrated Clinically Meaningful Pain Reduction at Follow-Up
Demonstrated Clinically Meaningful Pain Reduction at 7 Day Follow-Up PANCREATIC CANCER PAIN PROOF-OF-CONCEPT STUDY: ( Severe Pain 7 6 Moderate | g AGS ain a6 4 = 3.00 J a Pain & Soreaning Posted Days Follow-Up per (ras Hour) (#/-48 Hours) nett = Thine osayarsnctaes eve noe nsec woch wp belnesceda te
Slide 13: 100% of Responders Required Zero Opioid Use
100% of Responders Required Zero Opioid Use at 7 Days’ Lead-In Responding Subjects Completing 4-6 Week Follow-Up Remained Opioid Free Pain and Opioid Use is a Significant Issue in Pancreatic Cancer © ~75% of late-stage pancreatic cancer © ~20% are at risk for abuse and misuse? patients are prescribe
Slide 14: Path to Potential FDA Clearance
Path to Potential FDA Clearance First-in-Human Clinical Trial 1H 2025: Topline Results Human Pivotal FDADeNovo | FDA = Trial Submission —* | Clearance 2026: Topline Results 2028 leuil 2027 a Capital Expel avenene Revenue Generation Model Ub Catheter Disposables nditure: Annual Software License
Slide 15: Proof-of-Concept in Lead Indication Opens >$100 Billion Market Opportunity
Proof-of-Concept in Lead Indication Opens >$100 Billion Total Market Opportunity Potential Future Targets Market Opportunities | (3758 Initial Target 1 | $23B
Slide 16: Proven Team with Multiple Successful Exits
Proven Team with Multiple Successful Exits © @ ® Dr. Robert Schwartz Trent Smith Landy Toth ‘60 FOUNDER. CMO ‘iter FnaNcinLoFrceR CO-FOUNDER, CTO @ Brad Hauser Jenniter Cook + lover ot Waterman + Meseivcgwutto aaa + Machanlalengneermecica {istered sono sop ‘Ret Sou S08 Grvceenpe 3 erate aro + Se teo
Slide 17: Investment Summary
AUTONOMIX Investment Summary Unleashing the Power of Nerve-Targeted Treatments Ongoing trial with Proven team with multiple treatment of painand diseases of multiple near-term milestones successful exits, the nervous system Significant, sustained pain reducti demonstrated from initial lead-in patien
Slide 18: Autonomix Contact
Le AUTONOMIX Company Investor / Media Relations Astonomix adc ne. 21 s0a.9240775 OO) eae i, S Wooande 77380 (B_sxx0r0m:x@32K-c0m autonomix.com
Autonomix Medical — Investor Presentation (January 2025) on 6ix